Rocket Lab Retreats 54% From Peak as Sector Revaluation and Insider Sale Weigh on the Stock

Rocket Lab closed at €60.90 in German trading, 54% below its 52-week high, as sector-wide repricing and analyst target cuts weigh on the stock.

Rocket Lab's shares have been caught in a broad repricing of the aerospace and defense complex, a shift that has little to do with the company's own order book. In German trading on Friday, the stock closed at €60.90, leaving it 54% below its 52-week high of €133.80. Over the preceding seven sessions alone, the decline totaled 7.3%.

The backdrop is one of rising US Treasury yields and firmer oil prices, which together have triggered a wave of risk aversion across financial markets. According to media reports, the drop in Rocket Lab's share price was not driven by company-specific news but by this wide-ranging sell-off, with investors shedding technology and growth names in particular.

Wall Street Trims Targets, Keeps Its Faith

The sector-wide reassessment has fed directly into analysts' models. Gautam Khanna cut his price target from $120 to $90 while keeping a Buy rating on the stock, explicitly citing a disorderly valuation adjustment across aerospace and space names that has swept through the entire sector. Separately, Anthony Valentini initiated coverage of Rocket Lab with an Overweight rating and an $85 price target. Despite the headwinds, both houses continue to see upside in the shares.

TD Cowen likewise stuck with its Buy recommendation but lowered its target from $120 to $90, pointing to the same disorderly repricing of the broader aerospace and defense sector. Media reports indicate that Barclays also picked up coverage with an Overweight rating and an $85 target.

A Management Signal in a Nervous Market

Adding to the sector-specific cooling, a regulatory filing with the US Securities and Exchange Commission shows that CFO Adam Spice sold 140,157 shares on October 1. The transaction was executed under a pre-arranged trading plan pursuant to Rule 10b5-1. Even though such sales run on autopilot, they offer little reassurance in an already jittery sector environment.

Operational Momentum Runs Against the Market Tide

On the operational side, the picture looks markedly different. Roughly a week ago, Rocket Lab announced a multi-year agreement covering 20 Electron missions for Synspective — a contract the company described as the largest commercial arrangement for the Electron rocket in its history. The launches are scheduled to take place annually between 2028 and 2031. The deal lifted the total number of Electron missions booked by Synspective to 47 and secures a stable launch volume for the years ahead.

The phase in which contract announcements alone fueled sustained share-price enthusiasm has for now given way to a more sober reality. When institutional investors undertake sector-wide valuation corrections, what matters to shareholders is not merely the number of contracted launches stretching into the next decade, but above all a company's resilience against the industry's broader downtrend. Rocket Lab keeps delivering new orders — yet the tempo on the trading floor is currently set by the macroeconomic environment.